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Abstract  
Background: Early onset dementias (EOD) are rare neurodegenerative dementias that present before 65 
years. Genetic factors have a substantially higher pathogenetic contribution in EOD patients than in late 
onset dementia.  
Objective: To identify known and/or novel rare variants in major candidate genes associated to EOD by 
high-throughput sequencing. Common-risk variants of apolipoprotein E (APOE) and prion protein (PRNP) 
genes were also assessed.  
Methods: We studied 22 EOD patients recruited in Memory Clinics, in the context of studies investigating 
genetic forms of dementia. Two methodological approaches were applied for the target-Next Generation 
Sequencing (NGS) analysis of these patients. In addition, we performed progranulin plasma dosage, 
C9Orf72 hexanucleotide repeat expansion analysis and APOE genotyping.  
Results: We detected three rare known pathogenic mutations in the GRN and PSEN2 genes and eleven 
unknown-impact mutations in the GRN, VCP, MAPT, FUS, TREM2, NOTCH3 genes. Six patients were 
carriers of only common risk variants (APOE and PRNP), and one did not show any risk mutation/variant. 
Overall, 69% (n=9) of our EAOD patients, compared with 34% (n=13) of sporadic late-onset Alzheimer 
Disease (AD) patients and 27% (n=73) of non-affected controls (ADNI, whole genome data), were carriers 
of at least two rare/common risk variants in the analyzed candidate genes panel, excluding the full penetrant 
mutations. 
Conclusion: Our results show that EOD patients are characterized by polygenic mutations/risk alleles and 
that the genetic load without full penetrant mutations stays on higher than that observed in late-onset AD 
forms. Thus, we recommend the screening of all causative genes in larger EOD cohorts. 
This study suggests that EOD patients without full penetrant mutations are characterized by higher 
probability to carry polygenic risk alleles that patients with LOAD forms. This finding is in line with 
recently reported evidence, thus suggesting that the genetic risk factors identified in LOAD might modulate 
the risk also in EOAD. 
 
 
4 
 
Keywords 
Alzheimer’s disease; Frontotemporal dementia; Lewy body dementia; early onset dementia; Next 
Generation Sequencing; rare mutations; common variants 
5 
 
INTRODUCTION 
The term early onset dementias (EOD) refers to a group of progressive neurodegenerative diseases (e.g. 
Alzheimer’s disease (AD), frontotemporal dementia (FTD) or dementia with Lewy Body (LBD), affecting 
individuals aged between 45 and 65 years and it represents roughly 5% of dementia cases [1]. The 
symptoms of EOD are similar to those of late-onset AD and FTD. However, EOD is thought to be more 
severe and typically causes a rapid decline in health [2,3].  
Both AD and FTD are pathologically heterogeneous disorders, characterized by a complex genetic 
architecture that is not yet completely understood. The heritability rates of the different dementia subtypes 
range from 40 to 80% with EOD showing a higher genetic component than late-onset dementia (for review 
[4]).  
AD is clinically characterized by memory impairment and pathologically by the presence of amyloid  
peptide (the precursor of which is encoded by the APP gene) plaques and intraneuronal tangles of 
hyperphosphorylated forms of tau (a microtubule-associated protein encoded by the MAPT gene). The risk 
AD spectrum is composed of Mendelian genetic traits, genetic population risk factors (susceptibility genes), 
and nongenetic risk factors such as low cognitive reserve and head trauma [5,6]. The apolipoprotein E gene 
(APOE) 4 allele is a known population risk factor [7] that has been found to increase the risk of early onset 
Alzheimer’s disease (EOAD) [8]. Since its discovery, over 550 susceptibility genes have been suggested to 
increase the risk of AD [9], though the impact of most of these genes seems to be much lower than that of 
APOE [10,11]. In particular, the common variants with small individual effects jointly modify the risk and 
age at onset of AD and dementia, showing a stronger effect in carriers homozygous for APOE e4 [12]. 
Three genes have been identified to carry causative mutations for familial EOAD: amyloid precursor protein 
(APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) (for review [11]). The estimated mutation 
frequencies of these three genes are 1% for APP, 6% for PSEN1 and 1% for PSEN2. Together, they explain 
a genetic background of only 5-10% of EOAD patients, leaving a large group of autosomal dominant 
pedigrees genetically unexplained (for review [13]). This finding suggests that additional causal genes 
remain to be identified.  
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FTD is characterized by personality changes, language impairment, and deficits of executive functions 
associated with frontal and temporal lobe degeneration. At least nine autosomal dominant genetic traits have 
been associated with this pathology: mutations in MAPT, in the progranulin gene (GRN), and in the 
hexanucleotide repeat expansion C9orf72 genes are the most common, with the highest prevalence of GRN 
mutations found in populations of northern Italy [14-17]. GRN null mutations cause protein 
haploinsufficiency, leading to a significant decrease in the circulating progranulin levels in plasma, serum 
and cerebrospinal fluid (CSF) of mutation carriers [18-20]. Mutations in valosin-containing protein (VCP), 
TAR DNA-binding protein 43 (TARDBP), charged multivesicular body protein 2B (CHMP2B), fused in 
sarcoma (FUS), dynactin (DCTN1) and triggering receptor expressed on myeloid cell (TREM2) are rarer 
causes of this pathology [4,21]. Mutations in VCP [22], TARDBP [23], and TREM2 [24] have been observed 
in Italian families with a history of FTD. 
Interestingly, mutations in some of these genes, such as MAPT, GRN and C9orf72 have also been detected at 
low frequencies in AD patients, supporting the notion that a genetic heterogeneity exists for these diseases 
and that both diseases could form an AD-FTD disease continuum (for review [13]). An AD-like phenotype 
has also been described with the presence of a nonsense mutation in the prion protein gene (PRNP 
p.Q160*), which is responsible for inherited neurodegenerative spongiform encephalopathies [25]. In 
addition, the common coding polymorphism, methionine (M) to valine (V) at position 129 (M129V) in 
PRNP has been associated with EOAD, where the risk is higher for the VV genotype and is increased in 
patients with a positive family history [26].  
The recent development of extremely powerful, massively, parallel DNA sequencing technologies allows for 
the systematic screening of individual genomes for DNA sequence variations at base-pair resolution, 
enabling researchers to address the missing hereditability question and, thus, to uncover novel and/or 
potentially pathogenic rare variants in candidate genes. As previously documented [27-29], targeted re-
sequencing of a clinically significant gene panel may represent a powerful and cost-time-effective technique 
compared to the previously used sequential Sanger sequencing.  
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On this basis, we aimed to identify known and/or novel rare variants in candidate genes using next 
generation sequencing (NGS) and to evaluate the contribution of the common-risk variants in the APOE and 
PRNP genes in a selected cohort of Italian EOD patients. 
Recently, Cruchaga C et al. [30], confirmed that the genetic factors identified in LOAD modulate the risk 
also in EOAD cohorts, where the burden of these risk variants is associated with familial clustering and 
earlier onset of AD. In the present study, we estimated the genetic load in EOAD and LOAD, by identifying 
known and novel, both rare and common risk variants in candidate genes. We applied next generation 
sequencing (NGS) analysis in a selected retrospective cohort of Italian EOD patients and compared the 
frequencies of variants found with those estimated in samples from the ADNI database. 
 
MATERIALS AND METHODS 
Participants 
A retrospective sample of patients were was recruited in the context of studies investigating genetic forms of 
dementia at IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia Italy, Fondazione Case 
Serena, Pontoglio, Brescia, Italy and Fondazione Europea Ricerca Biomedica, Centro di Eccellenza 
Alzheimer, Ospedale Briolini Gazzaniga, Bergamo, Italy. Specifically, twenty-two patients fulfilled the 
following inclusion criteria for the present study: i) phenotype of AD, FTD, or LBD and ii) early disease 
onset (<65 years old), or iii) family history suggestive of an autosomal dominant genetic form of dementia 
(i.e., high or medium risk of identifying a mutation according to Loy and Woods criteria [31,32], as 
described below). Family history was collected through interviews with a first-degree relative or the spouse 
of the proband. The clinical and medical history of each family member was collected, and all of the 
available documentation for affected members was acquired. The probability of identifying a genetic 
mutation for AD or FTD was estimated considering the family medical history, the number of first and 
second-degree affected family members and the age of symptom onset, according to the criteria developed 
by Loy and colleagues [31]. According to Loy et al.’s criteria for AD, we defined a probability of 
identifying a genetic mutation of ≥86% as a high risk, a probability of 68-85% as a medium risk, a 
probability of 15-67% as a low risk, and a probability <15% as apparently sporadic/unknown significance. 
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Considering the same criteria for FTD patients, we considered an ≥88% probability of identifying a genetic 
mutation as a high risk, a 31-41% probability as a medium risk, and a probability <13% as a low risk. FTD 
pedigrees were also scored according to Wood’s pedigrees classifications criteria [32,33]. 
All participants were of Italian ancestry. Demographic features and clinical data (age at onset, MMSE) are 
reported in Table 1. As the sample was retrospectively pooled for the analysis, a standard protocol for 
biomarker characterization was not applied. When available, information on disease biomarkers status was 
included. Sixteen patients underwent one of the following examinations as part of their diagnostic exam: 
magnetic resonance imaging (MRI), positron emission tomography (FDG-PET) or Single Photon Emission 
Computed Tomography (SPECT), and/or lumbar puncture. MRI and PET/SPECT scans were visually 
evaluated to determine medial-temporal atrophy and hypometabolism, respectively. CSF samples were 
processed with local procedures to determine the level of Ab, tau and p-tau. Positive diagnosis was 
determined based on established cut-offs. 
Blood samples were collected from all patients. DNA and plasma were obtained according to standard 
procedures. Patients provided written informed consent. This study was approved by the local ethics 
committee (CEIOC, 62/2013). 
NGS panel analysis screening 
Genomic DNA was extracted from whole-blood samples with a commercially available kit according to 
standard procedures (GENTRA Minneapolis, MN, USA).  
Due to logistics issues, some samples were analysed through the use of the Ion Torrent PGM (Thermo 
Fisher Scientific, Waltham, MA USA) sequencer as NGS platform, by using a candidates genes panel, 
already described in Beck et al [27]. Briefly, for library construction, 5 ng of genomic DNA were amplified 
using the Ion Ampliseq Dementia Research gene panel (Ampliseq™, Thermo Fisher Scientific, Waltham, 
MA USA), and the Ion Ampliseq™ Library kit 2.0, according to manufacturer’s instructions. The generated 
amplicon library includes PRNP, PSEN1, PSEN2, APP (Amyloid Beta A4 Precursor Protein), GRN, MAPT, 
TREM2, CHMP2B, CSF1R (Colony Stimulating Factor 1 Receptor), FUS, ITM2B (Integral Membrane 
Protein 2B), NOTCH3 (Notch 3), SERPINI1 (Serpin Peptidase Inhibitor, Clade I (Neuroserpin), Member 1), 
TARDBP, TYROBP (TYRO Protein Tyrosine Kinase Binding Protein), VCP, SQSTM1 (Sequestosome 1). 
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Amplicons were ligated to Ion Torrent Barcodes/adapters P1 using DNA ligase. A first step of Agencourt 
AMPure XP bead (Beckman Coulter Inc., Brea CA, USA) purification was followed by nick-translation of 
adapter-ligated products and PCR-amplification. A second purification step using AMPure beads was 
performed and the concentration and size of the libraries were determined using an Agilent BioAnalyzer 
DNA High-sensitivity LabChip (Agilent Technologies, Santa Clara, CA USA). After dilution to 100 pM, 
libraries were clonally amplified on Ion sphere™ particles (ISP) by emulsion PCR with the Ion PGM™ 
template OT2 200 kit on the IonOne Touch 2 instrument according to the manufacturer’s instructions 
(Thermo Fisher Scientific, Waltham, MA USA). ISP were enriched using the Ion One Touch ES module, 
loaded on an Ion 314 chip kit V2 and sequenced with an Ion Torrent PGM System (Thermo Fisher Scientific 
, Waltham, MA USA). 
The remaining samples were analysed with the Illumina MiSeq platform and the TruSight One Sequencing 
Panel (Illumina, Inc., San Diego, CA, USA). This panel includes 125,395 probes targeting a 12-Mb region 
spanning 4,813 genes, among which the genes investigated by Ion Torrent PGM (PRNP, PSEN1, PSEN2, 
APP, GRN, MAPT, TREM2, CHMP2B, CSF1R, FUS, ITM2B, NOTCH3, SERPINI1, TARDBP, TYROBP, 
VCP, SQSTM1). The data regarding the other all genes were not used. The obtained sequence reads were 
aligned to the hg19 human reference sequence using the Burrow–Wheeler Aligner (BWA version 0.7.12). 
Duplicated reads were removed with Picard tools. Local realignment, recalibration, and variant calling were 
conducted with the Genome Analysis Tool Kit (GATK version 3.30). In order to have comparable results 
between the two sequencing approaches, we extracted from TruSight One Variant Call Format file (i.e., 
VCF file), the variants located in the regions sequenced by Ion Torrent PGM panel using BEDTools [34]. 
APOE genotyping 
Genetic variation at the APOE locus was determined by using the SNaPshot technique [35]. Briefly, assays 
for the APOE polymorphisms were performed using PCR reactions, which were subsequently combined to 
perform a single SNaPshot reaction. The amplification assay was designed with the following forward and 
reverse primers: APOE F: 5’ CCAAGGAGCTGCAGGCGGCGCA 3’ and APOE R: 5’ 
GCCCCGGCCTGGTACACTGCCA 3’. A product of PCR-amplification was used as a template in the 
SNaPshot Multiplex assay. The following specific primers were used: SNAP APOE112: 5’ 
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ACTGCACCAGGCGGCCGC 3’ and SNAP APOE158: 5’ATGCCGATGACCTGCAGAAG 3’. Finally, 
the samples were analysed, and allele peaks were determined using the ABI 3130xl genetic analyzer and the 
GeneMapper 4.0 program (Applied Biosystems, Foster City, CA, USA). 
C9Orf72 hexanucleotide repeat expansion  
PCR sizing of the GGGGCC hexanucleotide repeat was performed using previously published primers [36] 
on the ABI 3130xl genetic analyzer (Applied Biosystems, Foster City, CA, USA). The PCR reaction was 
carried out in a mixture containing 5% dimethylsulfoxide and 7-deaza-2-deoxy GTP in substitution for 
dGTP. Allele identification and scoring were performed using GeneMapper v4.0 software (Applied 
Biosystems).  
GRN plasma level measurement 
Plasma progranulin levels were measured in duplicate using an ELISA kit (Human Progranulin ELISA Kit, 
AdipoGen Inc., Seoul, Korea).  
Statistical and Bioinformatics analyses  
To classify a variant as rare, its frequency should be lower than 1% in at least one of the three reference 
databases (1000 Genomes Project http://www.internationalgenome.org/, Exome Sequencing Project 
http://evs.gs.washington.edu/EVS/ and Exome Aggregation Consortium http://exac.broadinstitute.org) [37]. 
In order to predict the functional consequences of non-synonymous variations, we exploited eight different 
bioinformatics tools, namely: SIFT, PolyPhen-2, FATHMM, phyloP, MutationTaster, LRT, and CADD and 
GERP++ [38-45]. A variant is classified as damaging if for at least three tools the mutation is predicted to be 
deleterious.  
Finally, to evaluate the mutation rate of the candidate genes selected in the NGS panel, we considered the 
gene damage index (GDI, a genome-wide, gene-level metric of the mutational damage that has accumulated 
in the general population), according to Itan et al. [46]. 
ADNI whole genome data: 
As a genetic replication cohort, we considered whole genome data from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). From the whole genome data, we extracted 
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the variants within the regions included in our sequencing panel and we applied the same variants annotation 
and classification performed for our sample.  
The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. 
Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, 
and clinical and neuropsychological assessment can be combined to measure the progression of Mild 
Cognitive Impairment (MCI) and early AD. The aim of ADNI project is to collect, validate and utilize 
heterogeneous clinical and biological data (including MRI and PET images, genetics, cognitive tests, CSF 
and blood biomarkers) to study the progression of AD. For up-to-date information see www.adni-info.org. 
RESULTS 
Target screening: Plasma progranulin and C9ORF72 analyses  
As a first step, progranulin plasma levels were assayed to screen for GRN null mutations (Table 1). One 
FTD patient was found to have progranulin plasma levels lower than the optimized cut-off value for null 
mutations detection of 61.55 ng/ml [19,47]. For 5 samples, it was no possible to detect the progranulin 
levels, due to the lack of plasma samples from these patients.  
None of the EOD patients carried the pathogenic hexanucleotide repeat expansion of C9ORF72. All patients 
were found to have less than 12 repeats [48]. 
 
NGS screening: identification of known and unknown rare variants  
Through the target re-sequencing of the 17 candidate genes panel, we identified fourteen rare variants in 
68% of the selected EOD cases (15 patients) (Table 1). These variants were defined as “pathogenic” when 
previously described in the literature, and they were classified as “damaging” by bioinformatic tools or as 
“unknown impact” when no data were available in literature and no deleterious effect was predicted by 
bioinformatics tools.  
Pathogenic variants  
Among the 14 identified rare variants, three were classified as pathogenic and damaging and have been 
described in Italian pedigrees unrelated to the patients analysed in the present study. Two variants were 
located in the PSEN2 gene (p.M239V=rs28936379 code case: 26_1, [49]; p.M239I=rs63749884 code cases: 
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30_1, L031, [50]); and one variant was a p.L271fs null mutation in the GRN gene (code cases: 29_1; L029) 
(Table 1).  
The PSEN2-M239V (Table 1, code: 26_1) was identified in an AD subject belonging to a pedigree with four 
affected family members. The patient presented with behavioural disturbances at the age of 50 years and 
likely inherited the disease from an affected parent who also showed behavioural disorders at a similar age. 
The affected parent’s twin sibling was also affected by a neurodegenerative disease, and a second-degree 
relative developed dementia before the age of 44 years. 
The PSEN2-M239I variant (Table 1, code: 30_1) was identified in an AD patient with disease onset at an 
age of 54 years. The proband belongs to a pedigree with four affected individuals in two generations. The 
patient likely inherited the disease from an affected parent who was diagnosed with AD before the age of 54 
years. The two siblings of this individual presented with behavioural problems that progressed to dementia 
before the age of 65 years . 
Another patient carrying the same M239I mutation (Table 1, code: L031) was diagnosed as having AD at 66 
years of age (onset of symptoms at 64 years). Her father and brother were affected with AD with onset at 66 
and 62 years of age, respectively. 
The GRN L271fs mutation was identified in a pedigree with seven affected subjects in two generations 
(Table 1, index case code: 29_1). The presence of this mutation was confirmed in other two siblings with 
FTD, characterized by age of onset of 60 and 61 years, respectively. 
Same L271fs mutation was identified also in another pedigree, where the index case (Table 1, code: L029) 
showed behavioural and speech disturbances at 62 years of age, diagnosed as FTD at 63 years.  
Finally, an heterozygous R93C mutation of the VCP gene was detected in a patient (Table 1, code: 36_1) 
affected by Paget’s disease of bone diagnosed at 44 of age and no signs of dementia at the last examination 
(47 years). Family history showed multiple individuals with FTD and Paget’s disease with autosomal 
dominant inheritance.  
Variants of unknown impact  
Two variants in the TREM2 gene (R62H=rs143332484, D87N=rs142232675, [51]) (Table 1) were observed 
in three of the 22 patients (14%), including a patient with LBD.  
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Moreover, in GRN gene, we found variants in the 5'UTR (rs76783532) and two rare missense variants 
(V77I=rs148531161; R19W=rs63750723; Table 1), which have been reported as “pathogenic nature 
unclear” and “not pathogenic”, respectively, in online database (www.molgen.en.ua.ac.be/FTDmutations). 
Accordingly, these missense mutations did not influence the progranulin level in plasma (Table 1). 
Other variants reported in online databases were those at 3'UTR of the FUS (rs80301724) and a missense 
mutation (V1183M=rs10408676) in NOTCH3 gene resulting “damaging” according to bioinformatics tools.  
Moreover, we detected rare mutations which have not been reported in the literature and databases. In 
particular, we found a mutation localized in the 5'UTR region and a missense mutation R93C (NM_007126: 
exon3: c.C277T:p.R93C) in the VCP gene, a deletion (NM_001203251:c.*55delA) in MAPT gene at 3’UTR 
region, a splicing variant (NM_000435: exon24: c.3838-1G>T) in NOTCH3 gene.  
 
Screening of known common variants  
All EOD patients were genotyped for the rs429358 and rs7412 polymorphisms in the APOE gene and the 
rs1799990 polymorphism in the PRNP gene. APOE 4 and PRNP 129Val are known to be risk alleles. The 
results indicated that the frequencies of the APOE 4 carriers and the PRNP 129Val carriers were 59% for 
both. Twenty (91%) of the 22 subjects carried at least one of the two risk variants; of these subjects, 27% 
(six out of 22) carried both the APOE 4 and the PRNP 129Val risk alleles. Six patients were carriers of at 
least one risk allele (APOE 4 or PRNP 129Val) (Table 1).  
 
One patient did not show any rare or common risk variants (Table 1).  
 
Comparison to whole genome data 
We compared and calculated the rare and common risk variants frequencies of the 17 candidate genes in our 
panel, with the data from ADNI whole genome sequencing database (ADNI, Alzheimer Disease 
Neuroimaging Initiative). In ADNI database, sporadic late-onset (38 patients), early onset (7 patients) AD 
cases and 272 controls subjects were available. In our sample, the results indicated that, excluding the full 
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penetrant mutations present in five patients, 9 patients (69%) showed ≥ 2 rare/common risk variants, 
compared with 13 (34%) and 73 (27%) observed in ADNI late-onset AD cases (LOAD) and controls, 
respectively (Chi-squared test: χ2=15.8, df=4, p=0.003; Table 2). If we add to our sample, the seven EOAD 
patients coming from ADNI database (n tot=20), the percentage of genetic load did not change (65%, n=13, 
Chi-squared test: χ2=17.9, df=4, p=0.001; Table 2).  
 
DISCUSSION 
This study suggests that EOD patients without full penetrant mutations are characterized by higher 
probability to carry polygenic risk alleles that patients with LOAD forms. This finding is in line with 
recently reported evidence [30], thus suggesting that the genetic risk factors identified in LOAD might 
modulate the risk also in EOAD. 
Moreover, This study reports a high throughput targeted re-sequencing of candidate dementia disease genes 
(PRNP, PSEN1, PSEN2, APP, GRN, MAPT, TREM2, CHMP2B, CSF1R, FUS, ITM2B, NOTCH3, 
SERPINI1, TARDBP, TYROBP, VCP and SQSTM1) in a selected cohort of EOD patients. we confirmed the 
role of GRN and PSEN2 genes in EOD, with the involvement of specific rare mutations already known. We 
also detected additional rare variants of unknown impact, located in the 5'/3' UTRs regulatory gene region of 
the GRN, VCP, MAPT and FUS genes, missense mutations in TREM2, GRN, NOTCH3 and VCP, genes 
and a splicing variant in NOTCH3 gene. According to the gene damage index (GDI) [46], mutations in these 
genes showed a value of “medium”, suggesting that these genes are not frequently mutated in healthy 
populations. This finding further implies that mutations in these genes could be disease-causing.  
Rare mutations of known significance 
Twenty three percent of the cases carried one pathogenic mutation for dementia. In line with previous 
studies [14], mutations in the PSEN2 gene, a rare cause of dementia worldwide, were frequent in our cohort 
(14%). Looking at the geographical distribution of PSEN2 mutations described to date, it is noteworthy that 
80% of these mutations were uncovered in two southern European countries, Italy and Spain. Thus, we can 
speculate that the non-homogeneous distribution of pathogenic mutations might be a result of genetic drift.  
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The GRN p.L271fs mutation is one of the most common GRN mutations worldwide. An analysis of this 
mutation in northern Italy showed that almost all families can be traced to a single founder. The origin of the 
mutation was dated to the Middle Ages at the turn of the first millennium, which explains the high frequency 
of this mutation in this geographic area [52].  
Rare mutations of unknown significance 
The role for novel variants of unknown significance in both common and rare dementia-associated genes 
was not exhaustively elucidated. Recently, novel, likely pathogenic variants were described in Italian 
patients with dementia [53]. 
We found two AD patients carrying the R62H mutation in the TREM2 gene, which has an unknown impact. 
A recent review on the correlation between TREM2 and AD [54], showed a meta-analytic association of this 
mutation with the late onset form of the disease. Our results also showed its involvement in the early onset 
form of AD. Since the two patients were also homozygous for the APOE 4 allele, this finding suggests 
interactions between TREM2 and APOE, as already demonstrated in vitro [55,56]. TREM2 is a lipid sensor 
that interacts with several AD risk factors involved in lipid metabolism, including APOE, which could 
decrease the threshold of disease occurrence [57]. 
In the specific case of two AD patients carrying the GRN p.V77I and R19W mutations, there is evidence of 
AD pathology in imaging and from biofluid biomarkers (Table 1). Since these missense mutations do not 
affect the progranulin levels, a pathogenic role of these mutations seems unlikely. However, we cannot 
exclude that they might have a pathogenic role other than “loss of function”, as no functional studies have 
been performed. Their presence in AD patients might rather indicate that this gene could be implicated also 
in the pathophysiological mechanisms leading to AD dementia. 
Our analyses showed the presence of additional rare variants located in the 5'/3' UTR regulatory gene region 
of the GRN, VCP, MAPT and FUS genes. A recent study reported that 3’UTR SNPs, such as rs80301724 in 
the FUS gene, are present in microRNA binding sites and could impact the post-transcriptional regulation, 
resulting in overexpression of the protein [58]. Also missense mutations in TREM2, GRN, NOTCH3 and 
VCP genes and a splicing variant in NOTCH3 gene were detected but, except for some information from 
bioinformatic tools, their specific functional impact was not assessed. The involvement of NOTCH3 gene in 
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dementia patients is interesting, both with a missense and with a splicing variant. This gene encodes a 
single-pass trans-membrane protein of 2321 amino acids, predominantly expressed in vascular smooth 
muscle cells in adults. It is well documented that NOTCH3 mutations play a critical role in the pathogenetic 
mechanism of vascular smooth muscle cell degeneration linked to CADASIL, one of the most common 
hereditary forms of stroke [59]. A recent hypothesis of AD [60] suggested that in CADASIL triggering 
events in the pathogenic cascade are not amyloid deposits but damaged blood vessels caused by 
inflammatory reactions that lead to ischemia, amyloid accumulation, axonal degeneration, synaptic loss, and 
eventually irreversible neuronal cell death. Inflammation and blood vessel damage are well recognized 
complications of AD, but what causes them and why the cerebral microvasculature is affected is still under 
debate [60]. Mutations in NOTCH3 gene are known to provoke inflammatory reactions and damage the 
brain in a wide variety of diseases [59], thus it is possible that one or more mutations in this gene may 
damage the microvasculature of the brain eventually leading that leads to dementia. The V1183M mutation 
was classified as a polymorphism in an Italian population [61], though the A allele frequency observed was 
0.006.  
Inclusion body myopathy with Paget’s disease of bone and IBMPFD is a recently identified autosomal 
dominant disorder due to mutations in the VCP gene affecting muscle, bone and brain. Interestingly, in our 
cohort we found the R93C (47832C>T) mutation in the VCP gene already described in patients with 
IBMPFD [62-65].  
Common variants 
In this study, we investigated the most established common risk variant for AD, the APOE 4 haplotype. 
The functional role of this polymorphism in AD pathogenesis is unclear. However, there is now strong 
evidence that APOE 4 could affect amyloid deposition [66]. Consistent with this evidence, in our cohort, 4 
haplotype carriers showed abnormal CSF biomarker levels of amyloid protein (Table 1). Consistent with this 
evidence, in our cohort all APOE4 carriers with available CSF were amyloid positive (Table 1), except for 
the case code 19_1 of which we discuss separately (see below). The frequency of the 4/4 genotype (n=4, 
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17%, exact confidence interval 3-32%) was higher than that commonly observed in the Caucasian 
population (1000 genomes), which is reported to be 2%.  
Moreover, we investigated the non-synonymous polymorphism p.Met129Val in the PRNP gene. Although 
there are no data on the functional effect of this polymorphism, we observed that the frequency of the risk 
variant allele G/Val was higher (59%) than the frequency reported in the general European population 
(frequency G/Val=33% reported by the Exome Aggregation Consortium). A recent meta-analysis showed 
that the p.Met129Val allele was associated with decreased disease risk in late-onset AD, but not in EOAD 
[67]. 
Six patients from the present cohort carry only common risk variants. They could be sporadic cases with 
onset at the extreme end of expected age range. However, the hypothesis that EOD is caused by mutations in 
genes not included in the NGS panel cannot be ruled out. In this regard, whole genome sequencing could 
foster the investigation of additional genetic factors underlying apparently sporadic EOD. Nonetheless, this 
task was beyond the scope of the present work. 
Additional observations  
Interestingly, fifteen (68%) of the 22 patients carried at least one rare variant (TREM2, GRN, PSEN2, 
MAPT, VCP, NOTCH3 or FUS). Among these, fourteen subjects carried also a common variant (APOE 
and/or PRNP). This result supports the hypothesis that EOD results from the interconnected mechanisms 
leading to neurodegeneration, where multiple genes can be implicated in one or more systems. Indeed, 
recent biochemical approaches [55,56] have shown interactions among these genes, such as between TREM2 
and APOE in vitro. These results strongly implicate a potential additive/synergic effect in EOD forms linked 
to the variable inter- and intra-familiar expressivity. To indirectly assess this effect, we found through the 
ADNI database that, excluding the full penetrant mutations, 71% of our sample showed ≥ 2 rare/common 
risk variants, as compared to 34% and 27% in sporadic late-onset AD patients and controls, respectively. 
This indicates that the EOD is more often associated with rare variants or risk alleles, and this could be 
useful in the genotype-phenotype correlations. Moreover, <10% of subjects, in our cohort, and in late onset 
AD patients, compared to 25% in a control group, were not carriers of any of the examined variants, which 
strengthens the idea of using an NGS whole/exome genome approach in a larger sample.  
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One AD patient with a very early age of onset (41 years) showed neither rare nor common-risk variants. 
Even an exome clinic investigation detected no rare or common risk variants. The family history was 
negative, as no other first-degree relatives were affected (neither the parents nor three siblings, two of whom 
were older than the patient, presented with the disease). Misdiagnosis is unlikely since this patient was 
positive for all AD biomarkers (abnormal CSF amyloid and tau levels, hypometabolism on FDG-PET, and 
medial temporal atrophy on MRI). Although we considered the possibility that the patient may show an 
extreme early-onset presentation of sporadic AD, this finding suggests that additional genes could be 
implicated in EOD, which strengthens the evidence that the panel of candidate genes needs to be expanded 
in the future. 
For the first time, the D87N mutation in the TREM2 gene was detected in a LBD patient with early onset. 
LBD is the second most common form of dementia after AD, with a prevalence rate of 4% in the general 
population [68]. The core symptoms of LBD include sleep disturbances, hallucinations, and cognitive 
deficits, accompanied within the first year by Parkinsonian motor symptoms. A recent twin study did not 
show a strong support for a genetic contribution to LBD. However, other studies have demonstrated that 
LBD aggregates in families and may have an autosomal inheritance pattern (for review [4]). To date, a few 
genetic markers have been identified. For instance, duplication and SNPs within   −synuclein genes 
have been associated with increased risk of LBD [69,70]. Moreover, mutations in the glucocerebrosidase 
(GBA) gene are more common in LBD, in addition to mutations in the MAPT or leucine rich repeat kinase 2 
(LRRK2) genes (for review [4]). Only one genome-wide linkage study has been performed among patients 
with familial LBD. A locus on chromosome 2q35-q36 was identified, though none of the genes in this 
region could explain the relation with LBD [71]. Although further confirmation is needed, the presence of a 
TREM2 mutation in an LBD patient adds a new actor to its genetic architecture. Mutations in TREM2, a 
microglial receptor, can lead to aberrant innate immune cell signalling, contributing to the initiation and 
propagation of several neurodegenerative phenotypes [72-83], including LBD. Moreover, this LBD patient 
was a carrier of the GG (Val/Val) PRNP risk genotype. This finding is in agreement with a previous study 
[84] that described a patient carrying the M232R mutation in the PRNP gene who developed dementia and 
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died six years after onset. An autopsy revealed the patient had dementia with Lewy bodies, not Creutzfeldt-
Jakob disease.  
Conclusions 
This study confirms the role of GRN and PSEN2 mutations in EOD, in the Italian population and provides 
evidence for roles of novel rare mutations located in the 5'/3' UTRs regulatory gene region of the GRN, 
VCP, MAPT and FUS genes, missense mutations in TREM2, GRN, NOTCH3 and VCP, genes and a splicing 
variant in NOTCH3 gene, with a “medium” GDI value. As previously observed, mutations in the PSEN2 
gene, a rare cause of dementia worldwide, are frequent in Italian patients. We also confirmed that mutations 
in GRN gene were present in both FTD and AD phenotypes. Moreover, six patients were carriers of only 
common risk variants (APOE and PRNP), and one patient did not show any mutation/variant. Overall, 69% 
(n=9) of our EAOD patients, compared with 34% (n=13) of sporadic LOAD patients and 27% (n=73) of 
non-affected controls, were carriers of at least two rare/common risk variants in the analysed candidates’ 
genes panel. 
Our results show that EOD patients are characterized by polygenic mutations/risk alleles and that the genetic 
load without full penetrant mutations stays on higher than that observed in late-onset AD forms. Thus, as 
recently supported by Bartoletti-Stella et al. we recommend the screening of all causative/candidate genes in 
larger EOD cohorts. 
Though our findings are consistent with results obtained from large cohorts [12], independent replications in 
larger samples are warranted. To further validate the role of polygenic risk variants in EOD, a systematic 
screening of rare and common variants in dementia-associated genes should be implemented in prospective 
cohorts with full clinical and biomarker characterization. 
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Table 1 Demographic, clinical features and presence of rare/common risk variants in candidate genes in early onset dementia 
c
o
d
e 
g
e
n
d
er
 
a
g
e
 a
t 
o
n
se
t 
C
li
n
ic
a
l 
d
ia
g
n
o
si
s 
G
en
et
ic
 r
is
k
 
M
M
S
E
 
A
b
 
ta
u
 
p
-t
a
u
 
A
tr
o
p
h
y
 
H
-M
 
P
R
G
N
 
(n
g
/m
l)
 
G
en
e 
c
D
N
A
 
C
h
a
n
g
e 
P
r
o
te
in
 
C
h
a
n
g
e 
F
u
n
c
ti
o
n
 
d
b
S
N
P
 
P
a
th
o
g
e
n
e
ti
c 
S
IF
T
 
P
P
2
 
L
R
T
 
M
T
 
F
A
T
H
M
M
 
C
A
D
D
 
G
E
R
P
+
+
 
p
h
y
lo
P
 
A
P
O
E
 
P
R
N
P
 
(M
1
2
9
V
) 
4_1 F 60 AD 
Apparently 
sporadic 
n.a. n.a. n.a n.a. n.a. n.a. 130 TREM2 G185A R62H Missense rs143332484 unknown T B N N T 8.315 -0.214 -0.173 e4/e4 Met/Met 
5_1 M 57 AD 
Unknown 
significance 
10/30 + + + + + 104 GRN G229A V77I Missense rs148531161 unknown T B N N T 10.3 -3.85 -0.864 e3/e4 Met/Met 
15_1 M 45 AD 
Unknown 
significance 
n.a. n.a n.a n.a n.a. n.a. n.a.               e3/e4 Met/Val 
16_1 M 51 AD 
Unknown 
significance 
4/30 n.a. + n.a. - n.a. 97               e3/e4 Met/Met 
19_1 F 41 AD 
Apparently 
sporadic 
n.a. + + n.a + + 111               e2/e3 Met/Met 
20_1 F 57 AD 
Unknown 
significance 
25/30 + + n.a - + 115               e3/e4 Met/Met 
21_1 F 48 AD 
Unknown 
significance. 
23/30 - - + + + 97               e3/e3 Met/Val 
25_1 M 52 AD 
Medium  
to high 
26/30 + - - + + 104 FUS *41G>A  3'UTR rs80301724 n.a.         e4/e4 Met/Met 
26_1 F 50 AD Medium 14/30 n.a n.a n.a + + 86 PSEN2 A715G M239V Missense rs28936379 yes D P D A D 19.5 4.92 9.213 e3/e3 Val/Val 
30_1 F 54 AD Medium 12/30 + n.a n.a - n.a. 85 PSEN2 G717A M239I Missense rs63749884 yes D D D A D 27.8 4.92 9.734 e3/e3 Met/Val 
            MAPT *55delA  3’UTR na n.a.           
32_1 F 60 AD Medium 22/30 n.a n.a n.a + + 102 TREM2 G185A R62H Missense rs143332484 unknown T B N N T 8.315 -0.214 -0.173 e4/e4 Val/Val 
            VCP 
-216/-215 
insGCTGCC 
 5’UTR  n.a.           
11_1 F 51 FTD High 23/30 +/- - + + n.a. 108 GRN -3895G>T  5’UTR rs76783532 n.a.         e3/e3 Met/Val 
29_1 M 56 FTD High n.a. n.a n.a n.a n.a. n.a. 39 GRN 811_814del L271fs Deletion n.a. yes         e3/e3 Met/Val 
14_1 M 57 LBD 
Unknown 
significance 
5/30 n.a n.a n.a n.a. n.a. n.a. TREM2 G259A D87N  rs142232675 unknown T D D N T 12.5 5.51 2.597 e3/e3 Val/Val 
34_1 F 49 AD 
Medium  
to high  
15/30 + - - - + 149 GRN C55T R19W Missense rs63750723 unknown T B N N T 8.7 0.13 0.17 e3/e4 Met/Val 
35_12 F 54 AD Medium n.a. n.a. n.a. n.a. + n.a n.a.               e3/e4 Met/Val 
36_1 M n.a. 
FTD- 
IBMPFD 
n.a. n.a. n.a. n.a. n.a. n.a. n.a. 145 VCP C277T R93C Missense  unknown  P D M D 3.8 19.39 2.70 e3/e4 Met/Val 
37_2 F 62 AD Low n.a. n.a. n.a. n.a. n.a. n.a. 138 NOTCH3 G3547A V1183M Missense rs10408676  D D  M D 3.9 3.09 2.32 e3/e4 Met/Met 
1413pcl M 62 
Familial 
Dementia 
Unknown 
significance 
5/30 n.a n.a. n.a. n.a. + 98               e3/e4 Met/Met 
29 
 
L028 F 63 AD Low 28/30 + + n.a. - + 161 NOTCH3 3838-1G>T  Splicing           e4/e4 Met/Val 
L029 F 62 FTD High 18/30 n.a n.a. n.a. + + n.a. GRN 811_814del L271fs Deletion n.a. yes         e3/e3 Met/Met 
L031 F 64 AD Medium 4/ 27 n.a n.a. n.a. n.a. + n.a. PSEN2 G717A M239I Missense rs63749884 yes D D D A D 27.8 4.92 9.734 e3/e3 Met/Val 
 
 
Keys: APOE, Apolipoprotein E (E4 risk allele); PRNP, Prion protein (G/val risk allele); PGRN/GRN, Progranulin; PSEN2, Presenilin 2; TREM2, 
Triggering receptor expressed on myeloid cell; FUS, Fused in sarcoma; MAPT, Microtubule-associated protein TAU; VCP, Valosin-containing protein; 
A, known damaging; B, benign; D, damaging; N, neutral; P, possibly damaging; T, tolerant; na, not available; CADD, CADD phred-scaled (a score of 
20 means 1% percentile highest scores of whole genome); dbSNP, single nucleotide polymorphism database (rs number); GERP, genomic evolutionary 
rate profiling score; GERP++, evolution score; MT, mutation taster; Phylop, phyloP100way vertebrate; PP2, PolyPhen2; SIFT, Sorting Intolerant from 
Tolerant; FATHMM, Functional Analysis through Hidden Markov Models (v2.3); LRT, Likelihood Ratio Test; AD, Alzheimer Disease; FTD, Fonto 
Temporal Dementia; LBD, Levy Body Dementia; FTD-IBMPFD, Inclusion Body Myopathy-Paget’s disease of bone; “Genetic risk” denotes the 
estimated probability of identifying a genetic mutation base on Loy and Wood criteria for AD and FTD; “Unknown Significance” denotes lack of 
information about diagnosis or clinical details; “Apparently sporadic” indicates no other affected case in the family; H-M, Hypo metabolism. 
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Table 2. Comparison of frequencies of rare (excluding the full penetrant) and common risk variants in our sample (This study) versus controls, late onset 
and early onset  AD patients (LOAD and EOAD respectively) obtained from ADNI database 
  Variants 
  n=0 n=1 n≥2 
  total 
Only 
rare 
Only 
common 
total 
Only 
rare 
Only 
common 
1 rare 
+ 
1 common 
1 rare 
+ 
2 common 
2 rare 
+ 
1 common 
2 rare 
+ 
2 common 
3 rare 
+ 
1 common 
total 
Groups Sample (N) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
 Controls (272) 67 (25) 9 (7) 123 (93) 132 (49) 2 (3) 28 (38) 25 (34) 8 (11) 8 (11) 0 (0) 2 (3) 73 (27)$ £ 
ADNI LOAD (38) 3 (8) 0 (0) 22 (100) 22 (58) 0 (0) 10 (77) 2 (15) 0 (0) 1 (8) 0 (0) 0 (0) 13 (34)$ £ 
 EOAD (7) 1 (14) 0 (0) 2 (0) 2 (29) 0 (0) 3 (75) 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 4 (57) 
This study AD (13) 1 (8) 0 (0) 3 (100) 3 (23) 0 (0) 2 (22) 4 (44) 2 (22) 0 (0) 1 (11) 0 (0) 9 (69)$ 
ADNI 
+ 
This study 
EOAD 
+ 
AD (20) 
2 (10) 0 (0) 5 (100) 5 (25) 0 (0) 5 (38) 5 (38) 2 (15) 0 (0) 1 (8) 0 (0) 13 (65)£ 
 
$ Chi-squared test: Controls vs LOAD-ADNI vs AD-our study, χ2=15.8, df=4, p=0.003 
£ Chi-squared test: Controls vs LOAD-ADNI vs EOAD-ADNI+AD-our study, χ2=17.9, df=4, p=0.001 
